CIIE: Join CIIE to embrace opportunities in Chinese market
25.5.2021 13:37:06 CEST | news aktuell GmbH | Press release
(Shanghai, China): Are you still searching for the right gateway to enter the Chinese market? Are you looking to boost your sales activities and network with potential trade partners in China? Are you seeking more media exposure that costs little to nothing? The China International Import Expo (CIIE) may be just the perfect channel to help you achieve these goals.
What is CIIE? The CIIE is the world's largest import expo and one of the top 10 business shows in the world. It is evolving to be a must-attend event for multinationals in every November in Shanghai.
Why attend it? Firstly, its scale and breadth of industries. Last year, it covered 360,000 square meters, or about the size of 70 football fields. Secondly, high-quality participants and exhibits. 10,000 exhibitors attended the first three editions, including many Global Fortune 500 companies and industry leaders. More than 1,300 products and services have made their global or Chinese debuts over the past three expos. Thirdly, opportunities to meet purchasers, land new projects and enter the Chinese market. Some 1.3 million Chinese buyers attended the first three editions. Over the past three expos, deals were signed worth more than $200 billion. Following these deals, a total of 319 projects from the first two expos, backed by foreign investment worth $15 billion, have been initiated and successfully launched in China. Fourthly, free media exposure. At CIIE, participants can promote their brands and gain media exposure, with global media outlets attending each year to report on the latest trends, products and innovations being shown at the fair. In the first three editions, more than 10,000 journalists covered the expo.
Intelligent Industry and Information Technology Exhibition Area in focus. Among the different segments at CIIE, the Intelligent Industry Information Technology Exhibition Area is one of the most important stages for manufacturing firms to showcase their latest products and technology. To manufacturing firms still wondering if you should take part in the CIIE, come see for yourself the companies that have already signed up for the fourth CIIE. You can also network with them and seek potential cooperation in advance.
Click on the following links to check out who they are!
List of first batch of exhibitors for 4th CIIE:
https://www.ciie.org/zbh/en/news/exhibition/official/20210315/27245.html
List of second batch of exhibitors for 4th CIIE:
https://www.ciie.org/zbh/en/news/exhibition/official/20210407/27547.html
List of third batch of exhibitors for 4th CIIE:
https://www.ciie.org/zbh/en/news/exhibition/official/20210512/27943.html
How to attend it? Please visit
https://www.ciie.org/ciie/f/book/register?locale=en
to REGISTER.
Contacts
Contact: Nie Qingxin
Tel.: 0086-21-67008870/67008988
Images
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma awarded ESA data procurement contract for space-based data on small space debris24.2.2026 10:53:34 CET | Press release
(Munich, February 24th, 2026) Vyoma, a Munich-based company providing Space Domain Awareness (SDA) capabilities, has been selected as the winner of the ESA tender on ”Data Procurement for Space-Based Statistical Data on Small Space Debris Phase 1”, funded via ESA‘s Space Safety Programme (S2P). ESA’s Meteoroid And Space debris Terrestrial Environment Reference (MASTER) model provides a description of the space environment around Earth, supporting satellite designers, operators and others with risk assessments. Currently, there exists a significant temporal and spatial knowledge gap for observations of space debris with sizes smaller than the detection limit of ground-based sensors. Vyoma's Flamingo-1 satellite is ideally positioned to generate the image data ESA is seeking. Flying “in-situ” at an altitude of 510 km, Flamingo-1's instrument can monitor large volumes of space at once. This sensor detects objects at long and short distances and captures small and fast objects reliably, im
Medi-Globe Launches mAI Companion® — the World’s First Real Time AI Assistant for Pancreatic EUS, Co Developed with IHU Strasbourg —Now MDR CE Marked and Available for Clinical Use in Europe24.2.2026 10:00:00 CET | Press release
Rohrdorf (Achenmühle), Germany — February 24, 2026 — Medi-Globe today announced the launch of mAI Companion®, a real-time medical AI solution designed to assist physicians in detecting pancreatic lesions during endoscopic ultrasound (EUS) — addressing one of the deadliest and most difficult-to-detect cancers, where earlier identification can dramatically change patient outcomes.
Grünenthal licenses exclusive Australian rights to Qutenza® to Clinect24.2.2026 08:43:52 CET | Press release
Aachen, Germany & Victoria, Australia, 24 February 2026 – Grünenthal, a global leader in pain management and related diseases, and Clinect Pty Ltd ("Clinect"), an Australian based company focussed on supporting access to unique products, announced today that they have entered into a definitive agreement whereby Clinect will have the exclusive Australian rights to Qutenza®, a topical, non-systemic, non-opioid patch indicated for the management of peripheral neuropathic pain. Under the agreement, Clinect will be responsible for obtaining marketing authorisation for Qutenza® in Australia and, upon approval, marketing and distributing the product in Australia.
Clean energy needs a clean planet: PLAN-B NET ZERO and everwave launch joint initiative20.2.2026 13:26:02 CET | Press release
(Berlin, Germany) A strong start to 2026. PLAN-B NET ZERO enters into a partnership with the Aachen-based environmental scale-up everwave. With the guiding principle ‘1 euro = 1 kilogram of waste’, the partners recovered 10,000 kilograms of waste from rivers in Cambodia at the start of the initiative Around 11 million tonnes of plastic waste enter the oceans every year. Without effective countermeasures, this volume could almost triple by 2040. Studies show that about 80 percent of marine plastic reaches the sea via roughly 1,656 rivers worldwide. To date, everwave has removed more than 2.4 million kilograms of plastic from rivers in Cambodia, Albania, and Thailand. The company uses waste collection boats, barriers, and manual cleanups to stop plastic before it reaches the oceans. At the same time, mobile sorting and recycling solutions return materials efficiently to the circular economy. AI support optimizes collection routes to clean as many waterways as possible in a sustainable wa
Grünenthal’s proprietary NaV 1.8 inhibitor enters clinical development18.2.2026 11:52:51 CET | Press release
Aachen, Germany, 18 February 2026 – Grünenthal announced today that the first healthy volunteers have been enrolled in a Phase I trial of its voltage-gated sodium channel (NaV) 1.8 inhibitor. The orally administered investigational medicine aims to provide a non-opioid therapy option across a range of acute and chronic pain conditions. Full results of the trial are expected in the second half of 2026.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom